Paul Lytle
Equibles does not estimate personal net worth.
Get an email with a short summary when Actuate Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACTU alertsAbout Paul Lytle
Paul Lytle is recorded as CFO at Actuate Therapeutics, Inc. (ACTU). The newest filing on record that lists Paul Lytle as CFO at Actuate Therapeutics, Inc. (ACTU) is dated April 6, 2026. The proxy statement of Actuate Therapeutics, Inc. reports total compensation of $1,006,361 for Paul Lytle in fiscal 2025, including a base salary of $435,363. Disclosed compensation is on record for 2 fiscal years. Actuate Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Actuate Therapeutics, Inc. includes Daniel M. Schmitt (CEO and Board Member), Andrew P. Mazar (COO), Aaron G.L. Fletcher (Board Member) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 6, 2026
Company network
Leadership on record at Actuate Therapeutics, Inc.
- Daniel M. Schmitt CEO, Board Member
- Andrew P. Mazar COO
- Aaron G.L. Fletcher Board Member
- Amy Ronneberg Board Member
- Dr. Dan Zabrowski Board Member
- Dr. Roger Sawhney Board Member
- Jason Keyes Board Member
- Martin H. Huber, MD Board Member
- Roger Sawhney Board Member
- Todd Thomson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Actuate Therapeutics, Inc. (ACTU) | Chief Financial Officer | $435,363 | $1,006,361 |
| 2024 | Actuate Therapeutics, Inc. (ACTU) | Chief Financial Officer | $210,000 | $1,896,096 |
Recent activity
No call appearances or filed executive changes recorded yet.